how many people use semaglutide Ozempic popularity among privately insured may worsen disparities Maximizing Semaglutide: Understanding the Doses

Jones, C

Public data shows that in 2024, the total sales of the three brands of semaglutide, Ozempic (for blood - sugar control, injection), Rybelsus (for blood - sugar control, oral) and Wegovy (for weight loss), exceeded $29 billion, only less than $500 million less than the "drug of the year", MSD's PD - 1 pembrolizumab

Animal studies indicate fetal growth restriction, ossification delay, skeletal variants, and reduced maternal weight gain, though more recent human evidence, including a 2024 cohort of 938 pregnancies, suggests no increased risk of major congenital malformations compared with insulin

This package saves versus buying the supplements individually

doi: 10.1210/jc.2010-2081 [DOI] [PubMed] [Google Scholar] 89.Buse JB, Rosenstock J, Sesti G, et al